Development of sandwich ELISAs that can distinguish different types of coxsackievirus A16 viral particles

详细信息    查看全文

• 作者：Xiangzhong Ye ; Lisheng Yang ; Jizong Jia…
• 关键词：Coxsackievirus A16 ; Hand ; foot ; and mouth disease ; Particle ; Antibody ; Enzyme ; linked immunoassay ; Vaccine
• 刊名：Applied Microbiology and Biotechnology
• 出版年：2016
• 出版时间：March 2016
• 年：2016
• 卷：100
• 期：6
• 页码：2809-2815
• 全文大小：1,114 KB
• 参考文献：Bruu AL (2003) Enteroviruses: polioviruses, coxsackieviruses, echoviruses and newer enteroviruses. A Practical Guide to Clinical Virology, Second Edition, pp. 44–45
  Bubeck D, Filman DJ, Cheng N, Steven AC, Hogle JM, Belnap DM (2005) The structure of the poliovirus 135S cell entry intermediate at 10-angstrom resolution reveals the location of an externalized polypeptide that binds to membranes. J Virol 79(12):7745–7755. doi:10.​1128/​JVI.​79.​12.​7745-7755.​2005 PubMedCentral CrossRef PubMed
  Butan C, Filman DJ, Hogle JM (2014) Cryo-electron microscopy reconstruction shows poliovirus 135S particles poised for membrane interaction and RNA release. J Virol 88(3):1758–1770. doi:10.​1128/​JVI.​01949-13 PubMedCentral CrossRef PubMed
  Chen Y, Li C, He D, Cheng T, Ge S, Shih JW, Zhao Q, Chen PJ, Zhang J, Xia N (2012) Antigenic analysis of divergent genotypes human enterovirus 71 viruses by a panel of neutralizing monoclonal antibodies: current genotyping of EV71 does not reflect their antigenicity. Vaccine. doi:10.​1016/​j.​vaccine.​ 2012.​10.​032
  Chong P, Guo MS, Lin FH, Hsiao KN, Weng SY, Chou AH, Wang JR, Hsieh SY, Su IJ, Liu CC (2012) Immunological and biochemical characterization of Coxsackie virus A16 viral particles. PLoS One 7(11):e49973. doi:10.​1371/​journal.​pone.​0049973 PubMedCentral CrossRef PubMed
  Ferguson M, Minor PD, Magrath DI, Qui YH, Spitz M, Schild GC (1984) Neutralization epitopes on poliovirus type 3 particles: an analysis using monoclonal antibodies. J Gen Virol 65(Pt 1) Jan:197–201. doi:10.​1099/​0022-1317-65-1-197 CrossRef PubMed
  Ferguson M, Wood DJ, Minor PD (1993) Antigenic structure of poliovirus in inactivated vaccines. J Gen Virol 74(Pt 4):685–690. doi:10.​1099/​0022-1317-74-4-685 CrossRef PubMed
  Fricks CE, Hogle JM (1990) Cell-induced conformational change in poliovirus: externalization of the amino terminus of VP1 is responsible for liposome binding. J Virol 64(5):1934–1945PubMedCentral PubMed
  Galazka A, Milstien J, Zaffran M (1998) Thermostability of vaccines. World Health Organization, Global Programme for Vaccines and Immunization
  Hou W, Yang L, He D, Zheng J, Xu L, Liu J, Liu Y, Zhao H, Ye X, Cheng T, Xia N (2015) Development of a coxsackievirus A16 neutralization test based on the enzyme-linked immunospot assay. J Virol Methods 215-216(0):56–60. doi:10.​1016/​j.​jviromet.​ 2015.​02.​010 CrossRef PubMed
  Li L, He Y, Yang H, Zhu J, Xu X, Dong J, Zhu Y, Jin Q (2005) Genetic characteristics of human enterovirus 71 and coxsackievirus A16 circulating from 1999 to 2004 in Shenzhen, People’s Republic of China. J Clin Microbiol 43(8):3835–3839. doi:10.​1128/​JCM.​43.​8.​3835-3839.​2005 PubMedCentral CrossRef PubMed
  Li R, Liu L, Mo Z, Wang X, Xia J, Liang Z, Zhang Y, Li Y, Mao Q, Wang J, Jiang L, Dong C, Che Y, Huang T, Jiang Z, Xie Z, Wang L, Liao Y, Liang Y, Nong Y, Liu J, Zhao H, Na R, Guo L, Pu J, Yang E, Sun L, Cui P, Shi H, Wang J, Li Q (2014) An inactivated enterovirus 71 vaccine in healthy children. New Engl J Med 370(9):829–837. doi:10.​1056/​NEJMoa1303224 CrossRef PubMed
  Li S, Tang X, Seetharaman J, Yang C, Gu Y, Zhang J, Du H, Shih JW, Hew CL, Sivaraman J, Xia N (2009) Dimerization of hepatitis E virus capsid protein E2s domain is essential for virus-host interaction. PLoS Pathog 5(8):e1000537. doi:10.​1371/​journal.​ppat.​1000537 PubMedCentral CrossRef PubMed
  Liu Q, Tong X, Huang Z (2015) Towards broadly protective polyvalent vaccines against hand, foot and mouth disease. Microbes Infect 17(2):155–162. doi:10.​1016/​j.​micinf.​ 2014.​11.​004 CrossRef PubMed
  Nakane PK, Kawaoi A (1974) Peroxidase-labeled antibody. A new method of conjugation. J Histochem Cytochem 22(12):1084–1091CrossRef PubMed
  Ren J, Wang X, Hu Z, Gao Q, Sun Y, Li X, Porta C, Walter TS, Gilbert RJ, Zhao Y, Axford D, Williams M, McAuley K, Rowlands DJ, Yin W, Wang J, Stuart DI, Rao Z, Fry EE (2013) Picornavirus uncoating intermediate captured in atomic detail. Nat Commun 4:1929. doi:10.​1038/​ncomms2889 PubMedCentral PubMed
  Ren J, Wang X, Zhu L, Hu Z, Gao Q, Yang P, Li X, Wang J, Shen X, Fry EE, Rao Z, Stuart DI (2015) Structures of coxsackievirus A16 capsids with native antigenicity: implications for particle expansion, receptor binding, and immunogenicity. J Virol 89(20):10500–10511. doi:10.​1128/​JVI.​01102-15 PubMedCentral CrossRef PubMed
  Schuck P, Rossmanith P (2000) Determination of the sedimentation coefficient distribution by least-squares boundary modeling. Biopolymers 54(5):328–341. doi:10.​1002/​1097-0282(20001015)54:​5<328:​:​AID-BIP40>3.​0.​CO;2-P CrossRef PubMed
  Shingler KL, Yoder JL, Carnegie MS, Ashley RE, Makhov AM, Conway JF, Hafenstein S (2013) The enterovirus 71 A-particle forms a gateway to allow genome release: a cryoEM study of picornavirus uncoating. PLoS Pathog 9(3):e1003240. doi:10.​1371/​journal.​ppat.​1003240 PubMedCentral CrossRef PubMed
  Singer C, Knauert F, Bushar G, Klutch M, Lundquist R, Quinnan GV (1989) Quantitation of poliovirus antigens in inactivated viral vaccines by enzyme-linked immunosorbent-assay using animal sera and monoclonal-antibodies. J Biol Stand 17(2):137–150. doi:10.​1016/​0092-1157(89)90004-8 CrossRef PubMed
  Somasundaram B, Lua LH (2015) Development of picornavirus-like particle vaccines. Pharmaceutical Bioprocessing 3(1):45–59CrossRef
  Wallis C, Menick JL (1962) Cationic stabilization—a new property of enteroviruses. Virology 16:504–506CrossRef PubMed
  Wang X, Peng W, Ren J, Hu Z, Xu J, Lou Z, Li X, Yin W, Shen X, Porta C, Walter TS, Evans G, Axford D, Owen R, Rowlands DJ, Wang J, Stuart DI, Fry EE, Rao Z (2012) A sensor-adaptor mechanism for enterovirus uncoating from structures of EV71. Nat Struct Mol Biol 19(4):424–429. doi:10.​1038/​nsmb.​2255 PubMedCentral CrossRef PubMed
  Yang E, Cheng C, Zhang Y, Wang J, Che Y, Pu J, Dong C, Liu L, He Z, Lu S, Zhao Y, Jiang L, Liao Y, Shao C, Li Q (2014) Comparative study of the immunogenicity in mice and monkeys of an inactivated CA16 vaccine made from a human diploid cell line. Hum Vacc Immunother 10(5):1266–1273. doi:10.​4161/​hv.​28083 CrossRef
  Zhu F, Xu W, Xia J, Liang Z, Liu Y, Zhang X, Tan X, Wang L, Mao Q, Wu J, Hu Y, Ji T, Song L, Liang Q, Zhang B, Gao Q, Li J, Wang S, Hu Y, Gu S, Zhang J, Yao G, Gu J, Wang X, Zhou Y, Chen C, Zhang M, Cao M, Wang J, Wang H, Wang N (2014) Efficacy, safety, and immunogenicity of an enterovirus 71 vaccine in China. New Engl J Med 370(9):818–828. doi:10.​1056/​NEJMoa1304923 CrossRef PubMed
  Zhu FC, Meng FY, Li JX, Li XL, Mao QY, Tao H, Zhang YT, Yao X, Chu K, Chen QH, Hu YM, Wu X, Liu P, Zhu LY, Gao F, Jin H, Chen YJ, Dong YY, Liang YC, Shi NM, Ge HM, Liu L, Chen SG, Ai X, Zhang ZY, Ji YG, Luo FJ, Chen XQ, Zhang Y, Zhu LW, Liang ZL, Shen XL (2013) Efficacy, safety, and immunology of an inactivated alum-adjuvant enterovirus 71 vaccine in children in China: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 381(9882):2024–2032. doi:10.​1016/​S0140-6736(13)61049-1 CrossRef PubMed
  
• 作者单位：Xiangzhong Ye (1)
  Lisheng Yang (2)
  Jizong Jia (1)
  Jinle Han (1)
  Shuxuan Li (2)
  Yajing Liu (2)
  Longfa Xu (2)
  Huan Zhao (2)
  Yixin Chen (2)
  Yimin Li (1)
  Tong Cheng (2)
  Ningshao Xia (2)
  
  1. Beijing Wantai Biological Pharmacy Enterprise, Beijing, 102206, China
  2. National Institute of Diagnostics and Vaccine Development in Infectious Diseases, State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, School of Life Sciences, Xiamen University, Xiamen, 361102, China
  
• 刊物类别：Chemistry and Materials Science
• 刊物主题：Chemistry
  Biotechnology
  Microbiology
  Microbial Genetics and Genomics
  
• 出版者：Springer Berlin / Heidelberg
• ISSN：1432-0614

文摘

Coxsackievirus A16 (CA16) is one of the major causative agents of hand, foot, and mouth disease (HFMD). No CA16 vaccine candidates have progressed to clinical trials so far. Immunogenicity studies indicated that different CA16 particles have much influence on the efficacy of a candidate vaccine. However, there are still no relevant reports on the methods of detecting different CA16 particles. In this study, we screened several monoclonal antibodies (mAbs) specific for different CA16 particles, and several sandwich enzyme-linked immunoassays (ELISAs) were developed to measure the different types of CA16 viral particles. The mAbs that could only bind denatured or empty capsids could not neutralize CA16. In contrast, the mAbs that could bind mature full particles or all types of particles showed obvious neutralizing activity. The thermal stability of different CA16 particles was evaluated using these sandwich ELISAs. The mature full particles were found to be more thermolabile than the other types of particles and could be stabilized by high concentrations of cations. These methods can be used to assist in the potency control of CA16 vaccines and will promote the development of a CA16 vaccine.